NCT03815942 - VAccination in Early and ADvanced Prostate caNCEr | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

June 24, 2020

Study Completion Date

June 24, 2020

Conditions

Intermediate Risk Prostate CancerCastration-resistant Prostate Cancer

Interventions

BIOLOGICAL

ChAdOx1-MVA 5T4 vaccine

ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10\^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10\^8 plaque forming units

DRUG

Nivolumab Infusion [Opdivo]

Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion

Trial Locations (2)

M20 4BX

Department of Oncology, The Christie NHS Foundation Trust, Manchester

OX3 7LE

Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford